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Background: Pyrimidine nucleoside phosphorylase (PyNPase) 
is an enzyme that converts 5'-deoxy-5-fluorouridine to 5-
fluorouracil. PyNPase is identical to platelet-derived endo-
thelial cell growth factor (PD-ECGF), and has angiogenic 
activity. In the present study of PyNPase activity in renal 
cell carcinoma, we tested for correlation between PyNPase 
activity and tumor extension, tumor proliferation and clini-
cal characteristics. 
Methods: Samples of tumor tissue and non-tumor tissue were ob-
tained from 10 renal cell carcinoma patients who underwent 
radical nephrectomy. These samples were examined, and 
PyNPase activity of the tissues was assayed. 
Results: PyNPase activity was significantly higher in renal can-
cer tissue than in normal tissue (p<0.01), and in immuno-
histochemical assays PyNPase was strongly stained in the cyto-
plasm of renal cancer cells. However, there were no significant 
correlation between PyNPase activity and tumor extension, ac-
cording to the results of histopathological examination and 
evaluation of vascularity of renal cancer tumor tissue. 
Conclusion: In this study, we did not observe correlation be-
tween PyNPase activity and renal cancer extension and 
proliferation. However, the present data suggest that 
pyrimidine-class drugs may be useful against renal cell car-
cinoma, because PyNPase activity is significantly higher in 
renal cancer tissue than in normal tissue. 
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Introduction
an enzyme that converts 5'-deoxy-5- fluorouridine (5'-
DFUR), a pro-drug of 5-fluorouracil (5-FU), to 5-FU 
[1, 21. Recently, it was reported that PyNPase expres-
sion is accelerated in various tumors [3]. Also, the 
higher the PyNPase activity in tumor tissue, the 
greater the anti-tumor effect of pyrimidine-class anti-
tumor drugs [4, 5]. Many reports have communicated 
that pyrimidine-class anti-tumor drugs are useful in 
patients with cancer of the breast and digestive or-
gans, especially colorectal cancer [6, 71, and are ex-
pected to be useful in treatment of other tumor types. 
 Although renal cell carcinoma (RCC) accounts for 
just 3% of all adult cancers, among urinary tract tu-
mors it is one of the most frequently occurring [8]. 
Interferon (IFN), the only drug which has been found 
to be useful in the treatment of RCC, produces a clini-
cal response corresponding to approximately 20% [91 
after radical nephrectomy. Therefore, more effective 
therapy for RCC is needed. 
 In 1992, using cloning techniques, researchers determined 
that PyNPase and PD-ECGF are the same substance [10, 
111. PyNPase was found to be angiogenic, and to greatly 
enhance tumor growth in vivo [121. Most RCCs are 
hypervascular, and overexpress angiogenic factors such as 
VEGF [13] and b-FGF [14]. Therefore, investigation into 
PyNPase activity in renal cancer tissue might aid in the 
evaluation of prognostic factors and treatments of RCC. 
 To determine whether pyrimidine-class anti-tumor drugs 
would be effective against RCC, we investigated PyNPase 
activity, histopathology and clinical characteristics of RCC 
patients who underwent radical nephrectomy. Further-
more, since PyNPase and PD-ECGF are the same sub-
stance, we also attempted to determine whether there is a 
relationship between PyNPase activity and tumor exten-
sion and proliferation.
Pyrimidine nucleoside phosphorylase (PyNPase) is
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Patients 
 Surgical specimens used in this study were obtained
from 10 RCC patients (6 men and 4 women; age 
range, 53-76 years; mean age, 64.3 years) who under-
went radical nephrectomy at Nagasaki University 
Hospital. Patients had not received therapy prior to 
the operation.
PyNPase activity 
 We measured PyNPase activity in 1-cm (1 cm X 1 cm) 
samples of tumor tissue and surrounding normal tissue, 
obtained from resected fresh specimens according to a 
method of Eda et al. [15]. Activity levels were ex-
pressed as the amount of 5-FU generated from lmg pro-
tein over a period of 60 minutes (,ug FU/mg protein/hr).
Relationship between PyNPase activity and tumor volume, 
angiogenesis and histopathologic characteristics 
 We examined the results of preoperative angiogra-
phy to determine the degree of vascularity, and inves-
tigated the relationship between vascularity and 
PyNPase activity. We used tumor diameter to estimate 
tumor volume, and examined the relationships be-
tween PyNPase activity and tumor volume and 
histopathologic characteristics.
PyNPase activity (,u 9Fu / protein / hr)
tumor tissue 
normal tissue
Localization of PyNPase activity 
 Immunohistologic staining was done using speci-
mens from resected renal tissue, fixed according to the 
AMEX method [161, and mouse anti-human thymidine 
phosphorylase monoclonal antibody (a gift from the 
Research Center, Nippon Roche K. K., Kamakura, 
Japan). PyNPase localization in RCC tissue was exam-
ined according to the procedure described by Sawase 
et al [ 17].
Results
High PyNPase activity in RCC tissue 
 As shown in Figure 1, PyNPase activity in surrounding 
normal renal tissue ranged from 2 to 28.5 jig FU/mg prote-
in/hr (mean, 16.6,ug FU/mg protein/hr), and in renal can-
cer tissue activity ranged from 13.1 to 260,ug FU/mg prot-
ein/hr (mean, 159.7,ug FU/mg protein/hr). In each patient, 
PyNPase activity was significantly higher in renal cancer 
tissue than in normal tissue (p<0.01), and these levels 
(within a single patient) differed on average by a factor 
of 5. In Patient 9, the cancer tissue was cystic rather than 






Fig. 1. PyNPase activity of renal cell carcinoma tissue and 
the surrounding normal renal tissue, in renal cell carcinoma 
patients. (A) PyNPase activity in each patient. (B) Mean of 
the PyNPase activity in all 10 RCC patients.
Tumor volume and PyNPase activity 
 Presumptive tumor volume was calculated from the 
operative specimens, in order to test for correlation 
with PyNPase activity in tumor tissue. Although 
PyNPase was observed to have angiogenic effects and 
to greatly enhance tumor growth, there was no signifi-
cant correlation between PyNPase activity and tumor 
volume (Y = 0.08, X = 148.4, R = 0.134) (Figure 2).
Tumor Volume
Fig. 2. Relationship between PyNPase activity in RCC tissue 
and tumor volume.
Gender and PyNPase activity 
 In general, the incidence of RCC is significantly 
higher in men than in women. In the present study, 
we found no correlation between gender and PyNPase 
activity in RCC patients (Table 1).
Table. 1. Relationship between gender and PyNPase activity 
in RCC tissue.
type ( INF-a vs INF-,8 ).
Table. 2. Relationship between PyNPase activity in RCC tis-
sue and histopathological findings.
                  N Tissue PyNPase activity T-test/ correlation 
                     (a g FU/mg protein/hr) 
 Stage I 11 6 177.7±65.0 
                                                        N.S. 
          11I 4 132.6±98.7 
Cell type Clear cell 7 181.9±65.8 
                                                        N.S. 
         Others 3 107.7±94.0 
Grade G-1 4 158.4±65.4 
                                                        N.S. 
          G-2 6 160.5 ± 92.0 
 INF a 7 163.2±92.0 
                                                        N.S. 
          /3 3 151.3±45.6
Sex N Tissue PyNPase activity T-test / correlation 
                  (.tg FU/mg protein/hr) 
male 6 171.5±97.5 
                                                   N.S. 
female 4 141.9±42.9
Vascularity and PyNPase activity 
 There was no correlation between results of preop-
erative angiography and PyNPase activity (Table 3). 
Even hypovascular RCC cells had high PyNPase activ-
ity levels.
Table. 3. Relationship between PyNPase activity in RCC tis-
sue and vascularity (as determined by angiography).
Histopathologic characteristics and PyNPase activity 
 As show in Table 2, we observed no significant correla-
tion between PyNPase activity and the following histo-
pathologic characteristics: tumor stage (early stage vs ad-
vanced stage), cell type (clear cell subtype vs others), 
tumor grade (grade-1 vs grade-2), and infiltration (INF)
                  N Tissue PyNPase activity T-test / correlation 
                         (µg PUnng protein/hr) 
Hypervascular 8 160.5 ± 85.5 
                                                           N.S. 
Hypovascular 2 156.3.± 63.3
Localization of PyNPase expression in RCC tissue and 
normal renal tissue 
 In normal kidney tubule cells, PyNPase expression 
was either weak or undetectable in the cytoplasm 
(Photograph A). In renal cancer cells, PyNPase was 
strongly expressed in the cytoplasm (Photograph B). 
Although there was no significant difference in local-
ization of PyNPase expression between normal kidney 
tubule cells and renal cancer cells, higher levels of ex-
pression were observed in renal cancer cells.
against RCC. Cytokines such as TNF-a , IL-1a and 
INF-y have been reported to increase PyNPase activity 
[ 18], and combined use of TNF-a and 5-FU has been 
reported to effectively inhibit tumor extension [191. 
Based on these findings, it is reasonable to conclude 
that a therapy which combines IFN and 5'-DFUR 
might be particularly effective against RCC. 
 PyNPase and PD-ECGF (which has been determined 
to be an angiogenic factor) are the same substance. 
Some metabolites from nucleic acids that have been 
decomposed by thymidine phosphorylase induce angio-
genic processes; in particular, chemotaxis and migra-
tion of bovine aortic endothelial (BAE) cells [201. PD-
ECGF has been reported to play a role in tumor exte 
nsion/proliferation [21], and increased PD-ECGF ex-
pression has been reported to result in microvascular 
proliferation in tumor tissue [3, 22]. RCC is generally 
hypervascular, and the clinical features of this disease 
are influenced by angiogenic factors such as b-FGF 
[23] and VEGF [24]. These findings suggest a rela-
tionship between PyNPase activity and RCC extension, 
proliferation and tumor volume. However, our results 
did not provide evidence for a relationship between 
PyNPase activity in RCC cellls and histopathologic 
characteristics such as tumor volume or angiography 
results. One possible reason for this finding is the 
small number of cases examined. Also, the present 
study did not include micro-level examination. Further 
study (involving a greater number of cases) will be 
needed in order to clarify the role of PyNPase in RCC. 
 In summary, there was strong staining of PyNPase 
in the cytoplasm of cancer cells, and PyNPase activity 
was significantly higher in RCC tissue than in normal 
tissue. This suggests that pyrimidine-class drugs may 
be effective against RCC.
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Discussion
 In the present study, we found that PyNPase activ-
ity is significantly higher in RCC tissue than in sur-
rounding normal tissues, and that it is localized in the 
cytoplasm of cancer cells; these results are similar to 
those of previous studies of PyNPase activity in colo-
rectal and breast cancers. These data suggest that 
pyrimidine-class anti-tumor drugs would be effective
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